- Home
- AZTA vs HRMY Comparison
AZTA vs HRMY Comparison
Compare AZTA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTA
- HRMY
- Stock Information
- Founded
- AZTA 1978
- HRMY 2017
- Country
- AZTA United States
- HRMY United States
- Employees
- AZTA N/A
- HRMY N/A
- Industry
- AZTA Industrial Machinery/Components
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- AZTA Technology
- HRMY Health Care
- Exchange
- AZTA Nasdaq
- HRMY Nasdaq
- Market Cap
- AZTA 1.8B
- HRMY 2.0B
- IPO Year
- AZTA 1995
- HRMY 2020
- Fundamental
- Price
- AZTA $33.18
- HRMY $32.01
- Analyst Decision
- AZTA Buy
- HRMY Strong Buy
- Analyst Count
- AZTA 3
- HRMY 9
- Target Price
- AZTA $50.67
- HRMY $54.22
- AVG Volume (30 Days)
- AZTA 987.3K
- HRMY 624.9K
- Earning Date
- AZTA 08-05-2025
- HRMY 08-05-2025
- Dividend Yield
- AZTA N/A
- HRMY N/A
- EPS Growth
- AZTA N/A
- HRMY 13.13
- EPS
- AZTA N/A
- HRMY 2.62
- Revenue
- AZTA $669,171,000.00
- HRMY $744,852,000.00
- Revenue This Year
- AZTA N/A
- HRMY $20.10
- Revenue Next Year
- AZTA $4.89
- HRMY $18.01
- P/E Ratio
- AZTA N/A
- HRMY $12.25
- Revenue Growth
- AZTA 8.56
- HRMY 20.62
- 52 Week Low
- AZTA $23.91
- HRMY $26.47
- 52 Week High
- AZTA $63.58
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- AZTA 70.08
- HRMY 41.88
- Support Level
- AZTA $29.79
- HRMY $31.70
- Resistance Level
- AZTA $31.42
- HRMY $33.69
- Average True Range (ATR)
- AZTA 1.39
- HRMY 0.88
- MACD
- AZTA 0.28
- HRMY -0.11
- Stochastic Oscillator
- AZTA 96.13
- HRMY 31.15
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.